The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and BPC ARG Double Strength LVLUP Health Peptides! Update as of 4.15.26 from the FDA. We will know more in July. This will allow these previously labeled category 2 research peptides to category 1 and allowable for compounding by FDA Compliance for Peptide Therapy and BPC 157 Holt Law